Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early-phase Biomarker-based Trial of NPC-1 for Alzheimer's Disease Pathology

NCT07236190 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT07236190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07236190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early-phase Biomarker-based Trial of NPC-1 for Alzheimer's Disease Pathology
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
April 1, 2026
Completion date
June 30, 2027
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease, mild cognitive impairment (mci), subjective cognitive decline (scd)